Build Rev 2


The US Solid valves used in the prototype were only rated by the manufacturer (via email correspondence) at around 1 million cycles. If a 1:1 (BiPAP) rhythm is selected, the solenoids will cycle 43,200 times a day, giving them a service life of less than one month continuous duty. Furthermore, they were not specified as “oxygen cleaned,” meaning oils accumulating within the valves during production may react with oxygen causing a combustion risk. The REV2 solenoid valves were specially manufactured by Spartan Scientific for these field ventilator units (in one week! Shout out to Jim Koller for making this happen); and are rated at 20 million cycles, or about 15 months of continuous duty at 1:1 second cycling. They can also be continuously energized for any modes that might include a manifold shutdown.

REV2 offers significant improvements in solenoid valve control/ flow distribution logic due to the replacement of two digital relay timers from the prototype with a single Programmable Logic Controller (PLC). The new PLC can be programmed on a laptop computer and programming transferred to the PLC through a serial interface. More flexibility in valve control and elimination of mechanical relays to increase anticipated service life were significant improvements.

Legal Disclaimer

The content on this website is being released in this manner to maximize the potential public benefit during this urgent need for measures to respond to the COVID-19 crisis, including promoting potential ventilator manufacturing methods.

The content has not been reviewed or approved by the U.S. Food and Drug Administration (FDA). Interested readers are encouraged to contact the FDA and review available FDA materials, including their guidance on ventilators as well as the Department of Health and Human Services (DHHS) declaration of liability immunity for medical countermeasures against COVID-19.

PLEASE NOTE: The content has not been peer reviewed. The Authors make no representations or warranties of any kind (express or implied) relating to accuracy, safety, usefulness, usability, marketability, performance, or otherwise of the content released here. The Authors disclaim all express and implied warranties of merchantability and fitness of the content for a particular purpose, and disclaims all express and implied warranties regarding non-infringement of any patent, copyright, trademark, or other rights of third parties in the content or use of the content, or in the making, using, or selling products or services by any person or entity.

People or entities attempting to use the content in any way, including creating products or offering services, assume all risk and responsibility related to those uses, including all legal and regulatory compliance, safety, efficacy, performance, design, marketability, title, and quality. The Authors assume no liability related to the actions of third parties and in respect of any infringement of any patent, copyright, or other right of third parties.

The content has not been used in testing with humans at this time.

The Authors’ names and logos are trademarks or other exclusive property of the Authors. Readers of the content shall not use the name or logo of any Author in any way for publicity, advertising, or other commercial purposes, including linked to the reader’s products or services. Readers of the content shall not make statements or representations that, in Author’s sole judgment, deliberately or inadvertently claim, suggest, or give the appearance or impression of a relationship with or endorsement by that Author.

The Authors are proud of their affiliation with the University of Colorado as alumni and, in the case of Dr. Thomas Greany, as a professor at the Anschutz Medical Campus. The Authors express their appreciation to the University of Colorado for its support of this project.